Array Digital Infrastructure Inc
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Array Digital Infrastructure, Inc. (NYSE: AD) owns and operates shared wireless communications infrastructure, including over 4,400 cell towers across the United States, enabling 5G and other wireless technologies for wireless carriers, government agencies, municipalities, wireless internet service providers, and broadband providers. The company provides tower rental services under master lease agreements; wireless roaming services; wireless eligible telecommunications carrier services; and retains certain wireless spectrum assets, with noncontrolling investment interests in additional towers. It serves consumer, business, government, and enterprise customers through colocation opportunities that support network expansion in rural and remote areas. Founded in 1983 and headquartered in Chicago, Illinois, Array Digital Infrastructure operates as a majority-owned subsidiary of Telephone and Data Systems, Inc. (NYSE: TDS). The company focuses on the wireless telecommunications infrastructure segment of the communication services industry, with operations concentrated in the United States. In August 2025, the company changed its name from United States Cellular Corporation following the completion of a transaction with T-Mobile US, Inc., under which T-Mobile acquired its wireless operations and certain spectrum assets for $4.4 billion, while Array retained its tower portfolio and entered a new master lease agreement for T-Mobile colocations on over 2,000 additional sites. It anticipates pending spectrum transactions with AT&T, expected to close by late 2025, and with Verizon, targeted for Q3 2026, alongside ongoing colocation growth initiatives that drove 68% year-over-year cash site rental revenue increases in Q3 2025. Leadership transitioned with Douglas W. Chambers serving as interim President and CEO, overseeing operational ramp-up and strategic monetization of retained assets.
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference®
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
AD Mortgage Survey Finds Growing Demand for Non-QM Lending Among Brokers
Alaris Equity Partners Income Trust Declares Q2 Distribution
Derm-Biome's DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs
Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
Is It Too Late to Buy Array Digital Infrastructure Inc (AD) After 3.1% Rally? GF Value Says Undervalued
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
Array completes sale of select spectrum assets to Verizon for $1.0 billion
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations
Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript
ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK
ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK
AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm